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Abstract
Here we report the NMR structure of the actin-binding domain contained in the cell adhesion
protein palladin. Previously we demonstrated that one of the immunoglobulin domains of palladin
(Ig3) is both necessary and sufficient for direct F-actin binding in vitro. In this study, we identify
two basic patches on opposite faces of Ig3 that are critical for actin binding and crosslinking.
Sedimentation equilibrium assays indicate that the Ig3 domain of palladin does not self-associate.
These combined data are consistent with an actin crosslinking mechanism that involves concurrent
attachment of two actin filaments by a single palladin molecule by an electrostatic mechanism.
Palladin mutations that disrupt actin binding show altered cellular distributions and morphology of
actin in cells, revealing a functional requirement for the interaction between palladin and actin in
vivo.
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As one of the most abundant proteins in the cell, actin participates in many important
cellular processes including cell motility, maintenance of cell shape, cell division, and
muscle contraction. Actin filaments can be assembled into diverse structures, such as the
tight bundles that support microvilli or stereocilia, or the highly dynamic actin networks that
are required for protrusive cell motility.1 The mechanism by which the cell coordinates the
assembly of each type of actin filament array is not fully understood, although numerous key
players have been identified.2, 3 Currently over 150 actin-binding proteins (ABPs) have been
identified that influence localization, polymerization dynamics, crosslinking, and
organization of actin.4 These ABPs have various means of regulating actin, which include
the ability to sequester monomeric actin (G-actin), nucleate filament formation, sever
filamentous actin (F-actin), generate branched arrays of actin, and cap actin filaments.
Moreover there are currently only a few known actin-binding motifs: the calponin homology
(CH),5 the Wiskott-Aldrich syndrome homology (WH2) module,6 the gelsolin homology,7
and the actin depolymerizing factor (ADF-H) domains.8 There are currently only a limited
number of structures of complexes of actin with ABPs, so a better structural understanding
of how ABPs interact with actin is still highly sought-after.
Palladin is highly conserved among vertebrate species and is a key regulator of actin
organization within migrating cells.9 Palladin is ubiquitously expressed in embryonic tissues
and is critical for normal development.9 Recently, we demonstrated that palladin is able to
both bind and bundle actin filaments in vitro and determined that one of the immunoglobulin
domains (Ig3) is an actin-binding domain.10 Current evidence suggests that palladin
occupies an unusual functional niche with roles as both an actin-crosslinking protein and a
molecular scaffold that binds several other actin-regulating proteins.10, 11
Palladin exists as multiple isoforms that are differentially expressed in various tissues, and
each isoform contains three to five copies of a distinctive Ig-like domain (Supplemental Fig.
S1). Ig domains are typically about 100 amino acids and consist of seven to nine β-strands
that adopt a sandwiched β-sheet fold. In addition to being the signature domain of the
palladin protein family, similar Ig domains have been described in a small number of other
vertebrate intracellular proteins, including myomesin,12 titin,13 MyBP-C,14 MyBP-H,14 and
filamin A (FLNa).15 The majority of these Ig-containing proteins are specifically expressed
in striated muscle, suggesting that this particular type of Ig domain may play a unique role in
creating the highly ordered cytoskeleton of the sarcomere.14, 16 Consistent with this premise,
inherited forms of heart disease are associated with mutations affecting the Ig domains of
myopalladin,17 titin,18, 19 and MyBP-C.20 Recent findings have shown high avidity F-actin
binding sites contained within tandem Ig domains of the nonmuscle F-actin crosslinking
protein FLNa, in addition to the low affinity conserved F-actin binding domains (ABDs).21
This highlights a new role for cytoskeletal Ig domains in directly binding F-actin, however
these studies did not identify the specific binding site on FLNa.
Palladin is a member of a subfamily of cytoskeletal proteins, all of which contain tandem Ig-
like domains, but are encoded as separate genes that are expressed in a more restricted
pattern: myopalladin is found only in heart and skeletal muscle22 and myotilin is expressed
mostly in skeletal muscle.23 The precise molecular function of palladin family Ig domains
has been a matter of debate recently. Myotilin has been shown to bind directly to F-actin, to
promote the bundling of actin in vitro, and moreover, generates unusual, super-robust actin
bundles in transfected cells.24 This overexpression phenotype is similar to that of
palladin.24, 25 Previous studies utilizing purified myotilin have identified the C-terminus,
containing two Ig domains, as the minimal F-actin binding fragment; but did not categorize
the binding site on myotilin further. This further motivated us to perform our own detailed
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analysis of palladin’s actin-binding activity. We recently showed that full-length purified
palladin binds directly to F-actin and crosslinks F-actin into bundles. Furthermore we
revealed that palladin’s Ig3 domain binds directly to F-actin, while the isolated Ig domains 4
and 5 do not, and that a palladin fragment containing the tandem Ig3-Ig4 domains efficiently
bundles actin.10 These previous results were the first to show that palladin directly organizes
actin into multi-filament arrays, and that certain sub-types of Ig domains are actin-binding
modules. However, it is currently unclear how palladin interacts with and bundles F-actin
and to what extent this interaction contributes to its role in regulating cell morphology and
motility.
In this work, we set out to elucidate the structure of the Ig3 domain of palladin, and thus
establish the basis for understanding its interaction with F-actin. Here, we present the NMR
solution structure of the palladin Ig3 domain. Structure-guided mutagenesis, coupled with
biochemical and cellular studies, reveal that palladin contains two F-actin binding sites that
are critically involved in targeting palladin to the actin cytoskeleton.
Results
Solution structure of Ig3 domain of palladin reveals two solvent-exposed basic patches
We determined the structure of the palladin Ig3 domain as a first step toward identifying the
actin-binding sites on the surface of palladin. In our earlier work, we assigned the complete
backbone and side chain resonances of Ig3.26 Assignment of NOEs and Ig3 structure
determination were accomplished by use of the CYANA program.27, 28 CS-Rosetta was
used to refine the structures. The lowest scoring models from CS-Rosetta were quite similar
to the initial models, however the hydrogen bond network is more complete and the N- and
C-terminal regions converged to a well-packed conformation (Fig. 1a & b). The final
structural statistics are summarized in Table 1. Fig. 1b shows a set of converged structures
of the palladin Ig3 domain. The 20 conformers representing the structures of Ig3 could be
superimposed with RMSD values of 0.7 Å (backbone atoms) and 1.0 Å (heavy atoms) for
ordered residues 6–100. The coordinates of the 20 energy-refined conformers that represent
the Ig3 solution structure were deposited (PDB ID: 2LQR)
The overall structure of Ig3 maintains the highly conserved Ig superfamily beta sandwich.
The upper β-sheet contains strands A, B, E, and D; while the lower β-sheet contains strands
A’, C/C’, F, and G. Members of the I-set of Ig domains typically contain two discontinuous
strands, A/A’ and C/C’ as observed here. In the Ig3 domain of palladin, these irregular
sections of the structure contain exposed basic residues (side chains highlighted in Fig. 1a)
that form two basic patches on the surface (Fig. 1c & d). The lysine residues contained in
these basic patches of Ig3 are not in conserved positions when compared to the other Ig
domains of palladin, but are conserved with similar domains of palladin family members
(Supplemental Fig. S1b). We also note that the geometry of the β-strand at Tyr 17 is
atypical, where the burial of the side chain induces a kink in the strand. While the interior of
the β-sandwich contains two cysteine residues (29 and 93) whose geometries could support
a disulfide bond, the presence of reducing agent in the NMR sample and the Cβ chemical
shifts for these residues indicate that a disulfide is not present in this structure.
Previously, when we reported that the Ig3 domain of palladin was able to bind F-actin
directly, we presented a homology model of the Ig3 domain based on the I1 domain of titin
(PDB ID: 1G1C).10 We predicted that the palladin Ig3 domain was an I-type
immunoglobulin-like domain and proposed that the interaction surface created by the amino
acid sequence, rather than large scale alterations of the I-type Ig fold, were responsible for
the association with F-actin. The NMR solution structures of the palladin Ig3 domain from
human (PDB ID: 2DM2) was recently deposited and the mouse (PDB ID: 2LQR) as
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presented here, which both confirm that the Ig3 domain has the structural features of an I-
type Ig domain, as presented in the homology model. Alignment of the two NMR solution
structure ensembles (Supplemental Fig. S2) shows the same protein fold for the two
structures, although some minor differences can be seen in the flexible regions of the
domain. The NMR solution structure of the palladin Ig3 domain and the identification of
basic patches support our previous speculation regarding the protein fold of Ig3 and
adaptations for binding to F-actin.
Basic patches are involved in actin binding
There are several positively charged residues on two opposite faces of Ig3 (Fig. 1c & d).
Such clustering of positively charged residues occurs on several other F-actin binding
proteins, namely AFAP-110 (614–617), thymosin β4 (17–20), villin (818–821), fascin (K22,
K43, and R398)29 and vasodilator stimulated phosphoprotein, also known as VASP (234–
237).30 Many of these actin binding proteins also contain a consensus sequence of (K-L-K/
R-K) and the motif is known as actin-binding domain 3 (ABD3).31 Likewise, the Ig3
domain of palladin contains a similar lysine-rich motif (K13-L-K15-H-Y-K18) in one of the
surface basic patches. These lysine residues are not found in the other Ig domains of palladin
that do not bind directly to F-actin, as highlighted in supplemental Fig. S1a. To test whether
actin binding involves basic residues, we made single, double, and triple lysine mutants
(K15A, K18A, K15/18A, K36A, K38A, K36/38A, K51A, and K15/18/51A) in Ig3, thus
neutralizing the charge of five residues on this surface. Actin binding and bundling activities
of the palladin mutants were assessed using co-sedimentation with F-actin. As shown in Fig.
2a & b (and Supplemental Fig. S3), F-actin binding was reduced significantly (P<0.05 for
means, t test) for mutations of lysine residues 15, 18, and 51, yet mutations to either basic
patch do not completely eliminate binding. In contrast, a K36/38A mutant failed to reduce
F-actin binding (Supplemental Fig. S3). These results suggest that the Ig3 domain of
palladin contains two major actin-binding patches (K15/K18 and K51) that are important for
direct binding interactions with F-actin.
Lysine mutations do not alter Ig3 conformation
To determine whether mutations to the basic patches on Ig3 produce local or global
perturbations to the structure and dynamics of the protein, we employed 2D 1H-15N HSQC
NMR. We did not detect any significant changes in either the chemical shifts or intensities
of the NH peaks when comparing the peaks observed in the WT and mutant protein
(K15/18/51A Ig3) HSQC spectra (See supplemental Fig. S4). Only minor NH chemical shift
changes are observed in the HSQC spectrum of the K15/18/51A Ig3 variant compared with
WT Ig3 for residues proximal to the mutated lysine residues. Overall the 1H-15N HSQC 2D
NMR spectrum of the lysine triple mutant overlays well with WT Ig3, indicating that these
mutations do not alter the structural integrity of the immunoglobulin fold.
Ig3 is sufficient for bundling actin
To determine the effect these lysine mutations have on the crosslinking activity of palladin,
differential sedimentation assays were used to detect actin bundles. Previous studies
demonstrated that the tandem Ig3-Ig4 domain is the minimal fragment of palladin required
for F-actin crosslinking. This work also revealed that the tandem Ig3-Ig4 domain exhibited
enhanced affinity for F-actin, over that of the Ig3 domain alone. However, the isolated Ig4
domain did not bind F-actin.10 Conversely, in our latest co-sedimentation assays, we
observed significant amounts of crosslinked F-actin in the presence of Ig3, with increasing
Ig3 concentration correlated with an increase in the amount of bundled F-actin (Fig. 3a & b).
One difference is that the original data was conducted at only one Ig3 concentration, thereby
limiting the binding capacity.10 In addition, close inspection of this previously published
data reveals levels of F-actin in the Ig3 bundles above actin only background levels The
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bundling data we present here for Ig3 shows a concentration dependence, where increasing
amounts of F-actin are found in the bundled pellet as the concentration of Ig3 is increased.
This is similar to what was previously reported for the Ig3-Ig4 differential sedimentation
assay, however, the apparent Kd for Ig3 is much weaker than that of Ig3-Ig4 (Supplemental
Fig. S5). We also observed bundles formed by Ig3 using fluorescence microscopy with these
altered ratios of actin:Ig3 (1:2 versus previous 1:1) (Supplemental Fig. S6). These bundles
appeared to be smaller than those observed for the tandem Ig3-Ig4, but were consistently
detected. These results indicate that while Ig3 is the minimal domain required for binding
and bundling of F-actin, that Ig4 plays an important, supplementary role in producing larger,
more complex bundles.
We next assessed the ability of the Ig3 lysine mutants to bundle actin using the co-
sedimentation assay. We quantified the relative amount of F-actin being bundled among
three mutant constructs. As shown in Fig. 3c & d, mutations to either basic patch containing
K15/18A or K51A, decreased actin bundling to that of F-actin alone background levels.
While mutating any of these lysine residues individually did not result in complete loss of F-
actin binding, it does result in complete loss of F-actin bundling. This indicates that loss of
binding at either site disrupts bundling and suggests that crosslinking occurs through
engagement of two actin filaments via two separate binding sites on the Ig3 domain.
Immunoglobulin domains of palladin remain monomeric in solution
To probe whether the Ig3 and/or Ig4 domains of palladin exist in solution as monomers, we
determined the native molecular mass of both the isolated domains as well as the tandem
Ig3-Ig4 domains. Sedimentation equilibrium data were collected at three different rotor
speeds and at three different protein concentrations (10, 20, and 40 µM). Single, ideal
species analysis of individual traces was performed using nonlinear, least-squares analysis
(NLLS) to determine the apparent molecular mass and effective oligomerization state of the
Ig domains of palladin. The concentration profiles and fits to the observed traces when using
a single-species model reveal that Ig3, Ig4 and tandem Ig3-Ig4 are all monomeric in solution
(Supplemental Fig. S7). At each loading concentration, the average molecular mass was not
significantly different than that predicted for the monomer and did not increase with
increasing concentration of protein. By analytical ultracentrifugation, we did not detect any
oligomers as highlighted in Table 2.
Palladin’s Ig3 domain plays a critical role in subcellular targeting
Endogenous 90 kD palladin has been shown to exhibit two distinct subcellular localization
patterns: cytoplasmic and nuclear.32, 33 Cytoplasmic palladin is largely concentrated within
actin-rich structures.9, 34, 35 We set out to test the hypothesis that palladin’s binding to F-
actin is required to maintain its localization within the cytoplasm. Single, double and triple
point mutations (K15A, K18A, K15/18A, K51A, and K15/18/51A) were introduced into a
plasmid encoding full-length GFP-tagged palladin and transfected into cultured COS-7 cells.
Two days after transfection, the cells were fixed, counter-stained with phalloidin to detect F-
actin and DAPI to detect the nuclei, and imaged. Metamorph image analysis software was
used to quantify the amount of palladin that co-localized with DAPI in the nucleus. The
results showed that palladin containing single point mutations (K15A, K18A, K51A) retains
a persistently cytoplasmic localization pattern (Fig. 4 and supplemental Fig. S8). However,
the double and triple point mutants (K15/18A, K15/18/51A) displayed a strongly nuclear
localization pattern in 98–100% of the transfected cells, suggesting the possibility that
palladin may be imported into the nucleus if the binding of palladin to actin is insufficiently
robust to retain it in the cytoplasm. To test this hypothesis, we designed a plasmid encoding
GFP-palladin with the entire Ig3 domain deleted (ΔIg3). Somewhat surprisingly, the
localization of the ΔIg3 mutant was largely diffuse, as it did not co-localize with either
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actin-rich structures nor was it efficiently localized to the nucleus (Fig. 4). These results
suggest that palladin’s Ig3 domain may interact with a second binding partner, in addition to
F-actin, which is required for robust nuclear import.
Palladin overexpression generates F-actin hyperbundles, requiring the Ig3 domain
Previous results have shown that overexpression of 90 kDa palladin in cultured astrocytes or
COS-7 cells results in the formation of either unusual super-robust actin bundles or star-like
actin multifilament arrays.36, 37, 38 We used the COS-7 cell transfection protocol described
above to examine the ability of palladin mutants to achieve this high level of actin
organization. In COS-7 cells transfected with empty vector, a few thin stress fibers are
usually observed (supplemental Fig. S7), whereas in cells expressing WT palladin, actin co-
localizes with palladin in distinctive “hyper-bundled” super-robust actin-rich structures, as
described previously36, 39, 40 (Fig. 4). Blind scoring of cells revealed that unusually large
actin arrays are observed in 61% of cells transfected with WT palladin. Similar results were
obtained when cells were transfected with palladin containing single point mutations K15A,
K18A, K51A (Fig. 4 and supplemental Fig. S7); however, the double and triple point
mutants generated super-robust actin bundles in only 3.7% and 9.3% of transfected cells,
respectively. No super-robust bundles were observed in cells transfected with the ΔIg3
mutant. These results suggest that direct binding of palladin to F-actin is likely to be
required for the generation of the distinctive palladin overexpression phenotype.
Discussion
The primary goal of this work was to determine which residues are critical for palladin to
bind and bundle F-actin. This knowledge is key to understanding the molecular basis that
governs palladin regulation of actin filament dynamics within the cell. Our basic approach
was to determine the structure of the Ig3 domain of palladin and then to use this structure to
guide mutagenesis studies. The results we have obtained provide new insight into the
manner in which palladin binds to actin and crosslinks actin filaments. They also provide
support for an electrostatic model for binding and bundling of F-actin by palladin.
Previous results were the first to show that the Ig3 domain of palladin is responsible for
organizing actin into multi-filament arrays, thus establishing that certain sub-types of Ig
domains are actin-binding modules.10 The structure of Ig3 was determined by using NMR-
derived constraints and reveals that the surface of this immunoglobulin fold contains two
highly basic patches. Recognizing that regions of contact between actin and actin-binding
proteins are often found to be rich in basic amino acids,30 we assessed the functional
relevance of the surface-exposed lysine residues on opposite sides of this domain. Charge
neutralization variants at either site severely hindered the ability of Ig3 to bind F-actin;
however, single mutations to either patch do not completely eliminate F-actin binding,
indicating that other residues also contribute to binding of F-actin. Based on the three-
dimensional structure of the Ig3 domain of palladin, structure-guided mutagenesis, and
biochemical and cellular studies, we show here that palladin contains two major actin-
binding sites, one containing lysine 15 and 18 and another containing lysine 51. The
presence of two F-actin binding patches in Ig3 also suggests that this domain may be
capable of crosslinking F-actin by a mechanism involving simultaneous association of two
actin filaments by a single Ig3 molecule.
Actin bundles are the primary organizational arrangement of actin in vivo and were initially
shown to form only in the presence of a tandem construct containing both the Ig3 and Ig4
palladin fragments.10 However, differential co-sedimentation assays and fluorescence
microscopy have revealed that Ig3 is in fact the minimal actin cross-linking fragment of
palladin, and can produce significant bundles at higher concentrations of Ig3. These Ig3
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initiated F-actin bundles appear to differ structurally from the more robust bundles created
by the tandem Ig3-Ig4 domain and further studies are underway to elucidate this difference.
Mutations of either basic patch significantly reduced actin crosslinking, suggesting a critical
role for both of these basic patch residues in the formation of actin bundles. This is also
consistent with a two actin-binding site model, which is further supported by our data
indicating that isolated Ig3 remains monomeric in solution and yet is capable of crosslinking
actin filaments. While the two binding site model implies a 2:1 (G-actin:Ig3) ratio, our
bundling co-sedimentation results for Ig3 support the opposite ratio (1:2). The lack of
agreement between the ratio of actin to palladin that promotes binding versus that required
for bundle formation, suggests the bundling mechanism is likely more complicated than a
simple two binding site model and bundling may require significant decoration of actin
filaments with palladin to overcome the electrostatic repulsion between filaments. Although
the sedimentation equilibrium data that we present here reveals that the Ig3 and tandem Ig3-
Ig4 domains both remain monomeric in solution, an alternative crosslinking mechanism for
full-length palladin could involve a conformational change in palladin induced by actin-
binding that results in dimerization, such as that observed for vinculin.41
It is also possible that contributions from the other Ig domains as well as other residues
within Ig3 of palladin may significantly alter the F-actin crosslinked structure and function.
Increased actin binding affinity and bundling was observed for tandem Ig3-Ig4, with greatest
affinity for full-length palladin. Likewise, palladin has multiple binding partners that also
interact directly with actin: α-actinin,42 vasodilator stimulated phosphoprotein (VASP),39
and profiling.40 It is currently unclear how these interactions contribute to palladin’s role in
regulating cell motility and morphology, yet it is clear that palladin is intimately linked to
actin organization both directly and indirectly.
This work highlights the importance of the Ig3 domain in binding and crosslinking of F-
actin via direct, electrostatically driven association. We have previously shown that the
interaction between the Ig3 domain and F-actin is driven by electrostatic interactions, as F-
actin binding dramatically increased as the salt concentration was lowered.10 In fact many
other actin-binding domains are rich in positive charge and long-range electrostatics
interactions may stabilize the polyelectrolyte nature of F-actin.43, 44 A detailed examination
of the charge density variations on F-actin by Angelini et al. revealed that the surface of F-
actin contains subdomains that are strongly anionic.45 Subdomain 1 of the actin monomer is
strongly anionic with a net charge of −10, which is almost 4 times higher than the overall
charge on actin. This electrostatic model for actin binding is relevant given the high density
of filaments in cells as well as the presence of ionic fluxes.45 Among the significant number
of actin-binding proteins with no obvious consensus F-actin binding site, the identification
of proteins containing lysine-rich clusters is expanding. We suggest that the Ig3 domain of
palladin be added to this list, which currently includes the DAIKKKL sequence found in
actin depolymerization factor (ADF), cofilin and tropomyosin,46 the KKEK and NLKK of
villin,47 KLKK of AFAP-110, KLRK in VASP, the KLKK found in thymosin β4,30
KKLKH in ciboulot domains 1–3,48 and KKGGKKKG sequence of myosin.49 Deletion or
charge reversal mutagenesis of these basic residues in previous studies has abolished the F-
actin bundling activity of these proteins, suggesting that bundling occurs as a consequence
of neutralization of the negatively charged F-actin surface.30, 50 The specific binding sites of
these proteins may be closely related to the surface charge distribution; however, this does
not exclude the significance of specific actin binding sites that rely on structural features and
compatible hydrophobic surfaces.
Binding studies carried out in the Hartwig and Lehman labs reveal that the immunoglobulin
repeats of filamin A (FLNa) contributes significantly to the actin binding strength of
FLNa.21 Moreover, they have recently put forth a model, based on 3D EM reconstruction,
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where Ig10 of FLNa binds to negatively-charged regions of F-actin.51 The FLNa residues
involved in actin binding are surface-exposed, basic amino acids (four lysine and one
arginine), but this binding interface has yet to be verified as important for actin binding.
Several of these lysine residues in the Ig10 domain of FLNa are located in similar positions
in palladin’s Ig3 domain, both in primary and tertiary structure (Supplemental Fig. S9).
These conserved lysine residues can also be identified in the Ig3 domain of myopalladin,
which suggests a common F-actin binding interaction motif.
The results presented here show that the Ig3 domain of palladin is both necessary and
sufficient for both binding and bundling of F-actin. Based on our cell-based experiments, we
also suggest that this domain of palladin is directly involved in organization of the actin
cytoskeleton. We have identified two clusters of basic residues on the surface of Ig3 that are
required for F-actin crosslinking. Electrostatic interactions are also a major determinant in
actin polymerization and many basic proteins cause both polymerization and bundling of
actin filaments. Ongoing studies in our lab indicate that the Ig3 domain of palladin is also
capable of inducing actin polymerization under non-polymerizing conditions, so
understanding how the electrostatic interactions between actin and palladin regulate actin-
dependent processes is a major challenge for the future. The approach we have taken and the
results we have obtained provide a foundation for this type of investigation. Our cell-based
experiments also reveal new details about the mechanism that regulates palladin’s distinctive
pattern of subcellular localization, as palladin is usually concentrated both in closely-spaced
puncta arrayed along the actins stress fibers and also within the nucleus in certain cell
types.32, 33 Our results show that double and triple point mutations within palladin’s Ig3
domain cause a redistribution of palladin from the cytoplasm to the nucleus, although a
palladin mutant lacking the Ig3 domain displays a diffuse localization pattern within the cell
such that the ΔIg3 mutant appears to partition equally between the cytoplasm and the
nucleus. These results not only indicate that the interaction between palladin and F-actin is
required to target palladin to actin-rich structures, but also suggest that a second molecular
interaction, also mediated by the Ig3 domain, may be required in order to recruit palladin
efficiently into the nucleus. Two different nuclear localization mapping tools (WoLF
PSORT and cNLS Mapper Tool)52 did not identify any recognizable nuclear import or
export sequences, which suggests that palladin is transported into the nucleus in a complex
with another protein. Previous studies have shown that the C-terminal half of palladin binds
to the transcriptional regulator MRTF,33 suggesting that MRTF might be a good candidate
for this role. Palladin binding partners, profilin and α-actinin-4, also localize to the nucleus;
however, neither protein binds to the C-terminal region of palladin. Therefore MRTF is the
most likely candidate at this point. Clearly, additional studies will be required to explore this
hypothesis.
Materials and Methods
Protein expression and purification
Plasmids containing the individual Ig3, Ig4 and tandem Ig3-Ig4 cloned from (M. musculus)
were previously inserted into a modified pMAL-c2x (New England BioLabs) expression
vector.10 The Ig3 domain of palladin is 99–100% identical among all orthologs in mammals
(Fig. S1c). Several lysine residue mutants were generated from the pMAL Ig3 construct,
including K15A, K18A, K15/18A, K36A, K38A, K36/38A, K51A, and K15/18/51A. All
Ig3 variants were generated using QuikChange site-directed mutagenesis (Stratagene,
LaJolla, CA), with sequences verified by DNA sequencing. The palladin Ig domains were
purified as previously reported.10 All Ig3 variants were examined by SDS-PAGE gel to
assess purity and protein integrity before being employed in biochemical assays.
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All NMR data were collected at 25 °C on 600 and 700 MHz Varian Unity INOVA (Palo
Alto, CA) spectrometers. Pulse sequences were provided by Varian BioPack and data were
processed with NMRPipe (One Moon Scientific).53 The NMR sample used for the structure
determination contained 0.3–0.8 mM protein in buffer containing 50 mM Tris-maleate (pH
6.0), 150 mM NaCl, 2 mM DTT, 0.01% sodium azide, and 10% deuterium oxide. All
backbone and side chain assignments were previously determined and deposited (BMRB ID:
15512).26 Distance restraints were obtained from isotope-edited 3D-NOESY
experiments: 15N-edited (τ=100 ms),54 13C-edited (τ=100 ms) and aromatic 13C-edited
(τ=150 ms) NOESY-HSQC.55
Structure calculations
Automated NOE cross-peak assignments and structure calculations56 with torsion angle
dynamics were performed using the program CYANA (version 2.2).28 Backbone torsion
angle constraints obtained from database searches with the program TALOS+ were
incorporated into the structure calculation.27 Simulated annealing with 20,000 torsion angle
dynamics time steps per conformer was performed in the CYANA structure calculations
using the default parameters. In the final cycle of the CYANA protocol, 20 conformers were
generated and further refined using CS-ROSETTA. The CS-ROSETTA protocol used here
is a simplified version of the RASREC (Resolution Adapted Structural Recombination)
method developed by Lange and Baker for solving NMR solution structures of proteins with
low contact order.57 The Ig3 domain is a 9-stranded β-sandwich with four non-canonical
loops that cross from the top β-sheet to the bottom β-sheet. This makes Ig3 an ideal
structural candidate for the RASREC method. The RASREC method has six stages that
cycle between generating Rosetta fragments, producing low energy models, and biasing
conformational search space towards low energy space. Stage I of the method begins with
chemical shift data, NOE constraints, and the traditional fragments used in a Rosetta protein
structure prediction. If β-strands are detected in the chemical shift data or from Rosetta
fragments, then all possible β-strands pairings are enumerated. In each independent
trajectory 0–2 β-strands pairings are enforced. In our simplified version of this protocol, we
limited the possible β-strands pairings to those that are known to be present in the Ig3
domain. We specified which strands could pair (i.e. β-strand 4 is paired anti-parallel with β-
strand 5); however we did not specify which residue positions were paired. The
experimental data and the computational method were used to determine the specific residue
pairings. This greatly reduces computational expense because we do not search topologies
with known incorrect β-strand pairings but the high-resolution details of the structure are
still determined by experimental data. Stages II-VI were performed as previously
described.57 Briefly, these stages iterate between selecting fragments and residue level β-
strand pairings from the lowest energy trajectories observed. This data is then used to guide
further computational protein folding trajectories. In total, greater than 1,000,000 trajectories
were run to produce the final structural ensemble. Final structure ensemble quality was
evaluated with PSVS58. The programs MOLMOL59 and MacPyMOL60 were used to
visualize the structures. The coordinates of the 20 energy-refined CYANA conformers of
Ig3 have been deposited in the PDB entry 2LQR). The chemical shifts of Ig3 were
previously deposited in the BMRB entry 15512).26
Actin co-sedimentation assays
The actin binding and bundling properties of the Ig3 variants were assessed using an adapted
actin co-sedimentation assay.10 Briefly conventional monomeric actin (G-actin) purified
from rabbit muscle acetone powder61(Sigma) was polymerized with an equal volume of 2X
actin polymerization buffer (20 mM Tris pH 8.0, 200 mM KCl, 5 mM MgCl2, and 4 mM
DTT at room temperature for 30 min. To assess binding of the Ig3 mutants with F-actin, a
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100 µL sample in 1X actin polymerization buffer containing actin at 10 µM and varying
concentration of Ig3 protein were incubated at room temperature for 1 h. The samples were
centrifuged at high speed (150,000 · g) in a Beckman-Coulter TLA 100 rotor for 30 min at
25 °C. For bundling assays, similarly prepared samples were centrifuged at low speed (5,000
· g) to pellet bundles of actin before removing supernatant for subsequent high-speed
centrifugation. The pellet was then resuspended in 100 µL of 0.1% SDS buffer (0.1% SDS,
25 mM glycine, and 25 mM Tris, pH 8.3). Actin and Ig3 proteins in both the supernatant and
solubilized pellet were separated using 12% SDS-PAGE gels. Protein bands were quantified
using ImageJ software62 and reported as % Ig3 bound in binding assays or % F-actin for
bundling assays. All binding and bundling assays were repeated at least three times.
Averaged data with standard deviation error bars are presented.
Fluorescence microscopy of actin filament bundles
Purified actin was co-polymerized at 10 µM concentration and in the presence or absence of
20 µM Ig3 upon addition of an equal volume of 2X actin polymerization buffer (20 mM Tris
pH 8.0, 200 mM KCl, 5.0 mM MgCl2, and 4 mM DTT) and G-actin buffer (2mM Tris pH
8.0, 1 mM MgCl2, 0.5 mM EGTA, 0.5 mM DTT, 0.2 mM ATP, 0.1 mM CaCl2, and 0.1 mM
KCl). After polymerizing for 2 h, the actin was diluted to 1 µM in 1X actin polymerization
buffer and stained with 2.5 µL of 66.6 µM Alexa Fluor-488 phalloidin. Each reaction was
further diluted to a final actin concentration of 50 nM. A 5 µL sample was placed between a
coverslip and glass slide and visualized by epifluorescence using a Nikon TE200-U
microscope with 60X objective lens and a Hamamatsu Orca-ER camera.
Analytical ultracentrifugation
Sedimentation equilibrium experiments were performed on an Optima XL-A analytical
ultracentrifuge using an An50Ti rotor (Beckman Instruments, Inc.). Samples were
sedimented at three different rotor speeds (25k, 35k, and 37k rpm). Absorbance data were
collected by scanning the sample cells at a wavelength of 280 nm at intervals of 0.001 cm in
the step mode, with six averages per step. The samples were judged to be at equilibrium
when at least three successive scans, each taken 2 h apart, were superimposable.
Sedimentation equilibrium was achieved within 48 h for all samples. Sedimentation
equilibrium profiles were edited using REEDIT (J. Lary, National Analytical Ultracentrifuge
Center, Storrs, CT) to extract the data between the sample meniscus and the bottom of the
sample cell. The edited files were then examined by nonlinear, least-squares (NLLS)
analysis using WINNONLIN (D. Yphantis, University of Connecticut, Storrs, CT; M.
Johnson, University of Virginia, Charlottesville, VA; J. Lary, National Analytical
Ultracentrifuge Center, Storrs, CT).
Cell culture, DNA constructs, and transfection
COS-7 cells were maintained in DMEM (GIBCO) supplemented with 10% FBS in the cell
incubator (37 °C, 5% CO2). Lysine residue mutants were generated from the phrGFPIIN-
palladin (M. musculus isoform #4) construct, including K15A, K18A, K15/18A, K36A,
K38A, K36/38A, K51A, and K15/18/51A. All variants were generated using QuikChange
site-directed mutagenesis and the same primers used previously to make mutations in Ig3
domain (Stratagene, LaJolla, CA), with sequences verified by DNA sequencing. The ΔIg3
variant of GFP palladin was generated from GFP-tagged full-length M. musculus palladin
(isoform #4) plasmid in phrGFP II-N vector using the procedure outlined here 63 and
verified by DNA sequencing. Cells were transfected with palladin expression constructs
using Fugene 6 (Roche Diagnostics Corp., Indianapolis, IN, USA) according to the
manufacturer’s protocol and examined 24 h following transfection. Cells were grown on
glass coverslips and fixed in 4% paraformaldehyde in PBS, then permeabilized in 0.2%
Triton X-100 and incubated with Alexa-fluor 568 phalloidin and DAPI (4',6-diamidino-2-
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phenylindole). Coverslips were examined with a Nikon TE200-U microscope with 60x
objective lenses, an optional 1.5x tube lens and a Hamamatsu Orca-ER camera. Images were
processed using Adobe Photoshop 7.0 (Adobe Systems Inc.). For analysis of super-robust
actin bundle formation, images of transfected cells were scored independently by two
observers blinded as to the cell identity, with a minimum of 20 cells per group. Nuclear
localization was quantified by measuring the degree of co-localization with DAPI, using
Metamorph image analysis software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
Ig3 immunoglobulin domain 3 of palladin
ABPs actin binding proteins
G-actin globular or monomeric actin
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Ig immunoglobulin
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• Mapping of the interaction surface on palladin highlights electrostatically driven
actin binding
• Binding interaction between F-actin and the Ig3 domain of palladin is critical for
cellular localization
• Basic residues may be a common immunoglobulin domain interface for acidic
residues on actin
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NMR structure of actin-binding domain of palladin (a) Ribbon diagram of M. musculus
palladin Ig3 domain, lowest energy structure from CYANA-CS-Rosetta (PDB entry 2LQR).
Nine β-strands are colored from N to C termini (A, red; A’, orange; B, yellow; C, green; C’,
dark green; D, cyan; E, blue; F, magenta; G, purple)60 (b) Overlay of 20 lowest energy
structures,59 with calculated RMSD for all ordered residues (6–100), backbone only = 0.7
and all heavy= 1.0. (c) Surface electrostatic potential of two faces of Ig3, highlighting two
basic patches containing either K51 or K15/K18 (blue, positive charge; red, negative charge;
and white, neutral). Charged surfaces calculated using PDB2PQR Server64.
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Basic patches on Ig3 surface are critical for binding F-actin. (a) Results of binding co-
sedimentation assays with F-actin, including control experiments indicated by * (actin,
K15/18A, and WT Ig3 alone). Supernatant (S) and pellet (P) fractions were analyzed by gel
electrophoresis. Wildtype and lysine point mutants of the Ig3 domain were purified and
assayed for actin binding by co-sedimentation. Mutations of the lysine residues at residues
15, 18, and 51 all significantly reduced binding to F-actin. (b) Quantitative analysis of the
amount of Ig3 bound in the presence of WT and mutant Ig3 domains. For all co-
sedimentation assays the Ig3 concentration was 10 µM and actin concentration was 20 µM,
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and each experiment was repeated at least three times with standard deviation error bars
shown.
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F-actin bundling by Ig3 domain of palladin. Increasing the concentration of Ig3 relative to F-
actin revealed that this domain is capable of bundling actin. (a) Differential centrifugation
assay was used to assess crosslinking by WT Ig3, where the samples were subjected to a low
speed spin, and actin bundles (B) in the pellet were collected before sedimenting the
remaining F-actin by ultracentrifugation and resolving the supernatant (S) and pellet (P)
from these spins by SDS-PAGE. (b) Quantification of actin bundling was analyzed by
densitometry of the actin bands to estimate the ability of palladin to bundle F-actin. In all
assays, the concentration of F-actin was held constant at 10 µM and the palladin was varied
from 10 µM to 40 µM. The percent of actin found in the low speed bundle is represented by
the black bar, soluble portion is white, and high speed pelleted actin is gray. (c) Wildtype
and mutant forms of Ig3 domain were also assessed for actin crosslinking using the same
differential centrifugation assay. Bundling assays carried out with basic lysine residues
mutations (K15/18A or K51A) of Ig3 eliminate F-actin bundling by palladin. (d)
Quantitative analysis of the amount of actin found in the bundle, supernatant and pellet in
the presence of WT and mutant Ig3 domains. Data are means ± standard deviation for three
or more separate measurements.
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Ig3 domain of palladin plays a critical role in subcellular targeting. Full-length palladin
(WT), single, double and triple point mutants (K51A, K15/18A, and K15/18/51A) and Ig3
deletion mutant (ΔIg3) were introduced into a plasmid encoding full-length GFP-tagged
palladin and transfected into cultured COS-7 cells. 24 hours after transfection F-actin was
stained with Alexafluor 568 phalloidin and GFP-tagged palladin variants were analyzed by
fluorescence microscopy. DAPI staining was used to detect the nuclei.
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Table 1
Structural statistics of NMR structures of palladin Ig3 domain
Number of distance restraints
  Total 1395
  Intraresidue (i = j) 167
  Sequential (|i - j| = 1) 330
  Medium range (1 < |i - j| < 5) 150
  Long range (|i - j| ≥ 5) 748
Average number of constraints per residue 13.7
Average number of long range distance constraints per residue 7.3
Average number of distance constraint violations per conformer
  0.1–0.2 Å 8.5
  0.2–0.5 Å 12.0
  >0.5Å 10.3
Average RMSD from mean coordinates (Å)
  Backbone atoms, all residues 1.1
  Backbone heavy atoms, all residues 1.2
  Ordered residues b, backbone heavy atoms 0.7
  Ordered residues b, all heavy atoms 1.0
Global quality scores b (raw/Z-score)
  PROCHECK G-factor (ψ and Φ) −0.56
  PROCHECK G-factor (all dihedral angles) −0.18
  MOLPROBITY clash score c 4.82
  Ramachandran plot summary (%)d
  Most favored 83.8
  Additionally allowed 16.2
  Generously allowed 0.0
  Disallowed 0.0
a
Residues in regular secondary structure elements: 9–13, 16–20, 24–32, 39–43, 46–48, 54–60, 63–69, 78–86, and 89–100.
b
Calibrated relative to a set of high-resolution X-ray crystal structures for which the corresponding mean structure-quality score corresponds to a
Z-score =0.0 55.
c
Number of serious clashes per 1000 atoms.
d
For ordered residues 6–100 as evaluated by MOLPROBITY62.
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Table 2






Ig3 12.0 kDa 11.5 ± 2 kDa
Ig4 11.8 13.4 ± 3
Ig34 26.6 21.8 ± 2
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